In patients with T2D and chronic kidney disease (CKD), why might a sodium-glucose co-transporter 2 (SGLT2) inhibitor be preferred over a GLP-1 RA? A. SGLT2 inhibitors reduce weight more effectively B. SGLT2 inhibitors have more primary evidence demonstrating benefit in CKD C. GLP-1 RAs are contraindicated in CKD D. SGLT2 inhibitors are more potent glucose-lowering agents
[Verified Answer]: In patients with T2D and chronic kidney…
Need help with your Renal, Fluid & Electrolytes case study or NCLEX preparation? Connect with a verified Nursing expert now.
